| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 423.08M | 422.67M | 458.30M | 704.27M | 598.37M | 282.25M |
| Gross Profit | 291.50M | 292.29M | 318.63M | 519.55M | 481.81M | 179.59M |
| EBITDA | 113.24M | 143.39M | 186.77M | 398.96M | 385.70M | 131.78M |
| Net Income | -1.28M | 19.52M | 61.59M | 244.07M | 220.78M | 39.28M |
Balance Sheet | ||||||
| Total Assets | 1.52B | 1.77B | 1.74B | 1.70B | 1.56B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 289.34M | 585.97M | 466.40M | 322.81M | 186.39M | 10.96M |
| Total Debt | 351.90M | 650.46M | 655.77M | 662.77M | 758.20M | 775.48M |
| Total Liabilities | 642.75M | 893.32M | 895.37M | 916.72M | 1.04B | 802.16M |
| Stockholders Equity | 874.17M | 874.40M | 844.97M | 780.96M | 524.30M | 530.67M |
Cash Flow | ||||||
| Free Cash Flow | 99.75M | 141.94M | 173.92M | 254.67M | 198.26M | 128.95M |
| Operating Cash Flow | 101.11M | 143.07M | 177.53M | 255.32M | 200.03M | 128.97M |
| Investing Cash Flow | -4.04M | -4.89M | -3.61M | -2.68M | -6.26M | -1.38B |
| Financing Cash Flow | -315.65M | -18.61M | -30.33M | -116.22M | -18.34M | 1.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $23.48B | 20.16 | 48.52% | ― | 2.94% | 4.57% | |
73 Outperform | $1.48B | 8.08 | 28.94% | ― | -0.38% | 35.78% | |
66 Neutral | $15.54B | 104.35 | 34.48% | ― | 9.04% | -56.79% | |
66 Neutral | $7.07B | 57.53 | ― | ― | 2.38% | -38.88% | |
63 Neutral | $5.44B | 7.84 | ― | 3.07% | -0.18% | -18.95% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
52 Neutral | $813.84M | ― | -0.15% | ― | -3.43% | -102.60% |
On August 20, 2025, Olaplex Holdings, Inc. acquired Purvala Bioscience, a Boston-based biotech company, for $10.5 million. This acquisition marks OLAPLEX’s first since its inception over a decade ago, underscoring its commitment to innovation in the haircare industry. The integration of Purvala’s bioinspired technologies is expected to enhance OLAPLEX’s product offerings, potentially leading to the development of next-generation, science-backed products. This strategic move is anticipated to strengthen OLAPLEX’s position in the market and benefit its stylist community and consumers.
The most recent analyst rating on (OLPX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Olaplex Holdings stock, see the OLPX Stock Forecast page.
Olaplex Holdings, Inc. Navigates Transformation with Balanced Growth and Challenges
Olaplex Holdings, Inc., a prominent player in the health and beauty sector, is known for its innovative hair care solutions, particularly its Complete Bond Technology™ that enhances hair strength and health. In its latest earnings report for the second quarter of 2025, Olaplex reported a modest increase in net sales by 2.3% to $106.3 million, despite a net loss of $7.7 million compared to a net income of $5.8 million in the same period last year. The company’s performance across different sales channels varied, with professional and direct-to-consumer channels showing growth, while specialty retail saw a decline.